Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Payables (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Payables data on record, last reported at $1.1 million in Q3 2025.

  • For Q3 2025, Payables fell 63.49% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, down 63.49%, while the annual FY2024 figure was $2.3 million, 58.03% down from the prior year.
  • Payables reached $1.1 million in Q3 2025 per GOSS's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Payables topped out at $5.5 million in Q4 2023 and bottomed at $363000.0 in Q3 2022.
  • Average Payables over 4 years is $2.2 million, with a median of $2.2 million recorded in 2023.
  • Peak YoY movement for Payables: surged 361.32% in 2023, then crashed 63.49% in 2025.
  • A 4-year view of Payables shows it stood at $1.5 million in 2022, then soared by 278.75% to $5.5 million in 2023, then plummeted by 58.03% to $2.3 million in 2024, then crashed by 51.88% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.1 million in Q3 2025, $1.9 million in Q2 2025, and $3.4 million in Q1 2025.